EMBC,SPTX Stock Price and Quote

Aug 11, 7:10 AMSecurities fraud class action filed against Embecta alleging it misled investors on insulin pen needle product strength

Peers: OSUR LMAT ICUI MASS MMSI TFX VMD RMD VCYT BFLY

| Held by: IWM VTI IWN VXF FNDA DES SCHA VFVA VTWO ISMD

Index	RUT
Market Cap	284.71M
Enterprise Value	1.57B
Income	87.50M
Sales	1.02B
Book/sh	-10.81
Cash/sh	3.85
Dividend Est.	0.25 (5.01%)
Dividend TTM	0.46 (9.15%)
Dividend Ex-Date	Aug 27, 2026
Dividend Gr. 3/5Y	58.74% -
Payout	37.05%
Employees	1850
IPO	Mar 22, 2022

P/E	3.39
Forward P/E	2.85
PEG	-
P/S	0.28
P/B	-
P/C	1.30
P/FCF	1.73
EV/EBITDA	4.85
EV/Sales	1.54
Quick Ratio	1.17
Current Ratio	1.68
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	1.48
EPS next Y	1.76
EPS next Q	0.29
EPS this Y	-37.80%
EPS next Y	-3.95%
EPS next 5Y	-12.89%
EPS past 3/5Y	-25.52% -
Sales past 3/5Y	-1.47% -0.10%
EPS Y/Y TTM	4.11%
Sales Y/Y TTM	-7.60%
EPS Q/Q	-53.64%
Sales Q/Q	-8.05%
Earnings	Aug 07 BMO
EPS/Sales Surpr.	110.68% 6.75%

Insider Own	7.85%
Insider Trans	2.65%
Inst Own	83.68%
Inst Trans	-13.19%
ROA	7.22%
ROE	-
ROIC	11.83%
Gross Margin	59.63%
Oper. Margin	26.38%
Profit Margin	8.59%
SMA20	31.32%
SMA50	44.91%
SMA200	-40.14%
Trades

Shs Outstand	56.66M
Shs Float	52.21M
Short Float	12.80%
Short Ratio	3.21
Short Interest	6.68M
52W High	15.55 -67.68%
52W Low	2.77 81.41%
Volatility	11.22% 6.25%
ATR (14)	0.31
RSI (14)	73.36
Beta	0.86
Rel Volume	1.17
Avg Volume	2.08M
Volume	1,282,636

Perf Week	43.57%
Perf Month	56.06%
Perf Quarter	61.06%
Perf Half Y	-50.05%
Perf YTD	-57.70%
Perf Year	-63.95%
Perf 3Y	-75.88%
Perf 5Y	-
Perf 10Y	-
Recom	3.25
Target Price	4.00
Prev Close	4.75
Price	5.03
Change %	5.79%

Date	Action	Analyst	Rating Change	Price Target Change
May-06-26	Downgrade	BTIG Research	Buy → Neutral
Apr-10-25	Initiated	Mizuho	Neutral	$15
Dec-02-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$13 → $20
Nov-27-24	Upgrade	BTIG Research	Neutral → Buy	$26
Oct-20-23	Initiated	Wolfe Research	Peer Perform
Jan-06-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$28
Sep-08-22	Initiated	BTIG Research	Neutral
Aug-01-22	Initiated	Morgan Stanley	Equal-Weight	$33
Jun-21-22	Initiated	BofA Securities	Underperform	$25

Today 04:24AM	Embecta Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - EMBC (PR Newswire) +5.79%
Aug-11-26 07:07AM	EMBC Investor Announcement: Embecta Sued on behalf of Investors to Recover Losses after Insulin Pen Issues Lead to 57% Stock Drop (PR Newswire)
Aug-10-26 07:00AM	Kaplan Fox Encourages Embecta Corp. (EMBC) Investors with Losses to Contact the Firm Before August 17, 2026 (Newsfile) +12.90%
Aug-08-26 08:30AM	Embecta Corp. Q3 2026 Earnings Call Summary (Moby)
Aug-07-26 03:00PM	Embecta Corp (EMBC) (Q3 2026) Earnings Call Highlights: Strong Sequential Recovery and Raised ... (GuruFocus.com) +26.29%
06:30AM	Loading…
06:30AM	Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results (GlobeNewswire)
06:00AM	embecta Announces Quarterly Cash Dividend (GlobeNewswire)
Jul-27-26 07:30PM	Kaplan Fox Urges Investors of Embecta Corp. (EMBC) with Significant Losses to Seek a Leadership Role Before August 17, 2026 (Newsfile)
04:40AM	Embecta Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - EMBC (PR Newswire)
Jul-23-26 05:00PM	embecta to Report Fiscal Third Quarter Financial Results (GlobeNewswire)
Jul-21-26 08:30AM	Kaplan Fox Encourages Investors of Embecta Corp. (EMBC) Who Suffered Losses to Contact the Firm Before August 17, 2026 (Newsfile)
Jun-25-26 05:23AM	Embecta Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - EMBC (PR Newswire)
Jun-18-26 10:36AM	Embecta Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights EMBC (Business Wire)
Jun-16-26 06:30AM	embecta appoints Nimish Muzumdar as SVP and President, North America (GlobeNewswire)
Jun-05-26 07:25PM	Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
05:00PM	Loading…
Jun-01-26 05:00PM	embecta to Participate in Investor Events (GlobeNewswire) +6.08%
May-21-26 08:20PM	Levi & Korsinsky Investigating Whether Embecta Corp. (EMBC) Misled Investors - Securities Law Violations Possible (Newsfile) +8.50%
May-18-26 07:13AM	Embecta acquires Owen Mumford for $172.6m (Medical Device Network)
07:10AM	Embecta closes Owen Mumford acquisition for up to $201M (MedTech Dive)
May-15-26 09:00AM	embecta Completes Acquisition of Owen Mumford Holdings Limited (GlobeNewswire)
May-08-26 09:00AM	embecta to Participate at the 2026 BofA Securities Global Health Care Conference (GlobeNewswire)
May-05-26 04:53PM	Embecta Corp. Q2 2026 Earnings Call Summary (Moby) -57.84% -8.72%
06:30AM	Embecta Corp. Reports Second Quarter Fiscal 2026 Financial Results (GlobeNewswire)
06:30AM	embecta Announces Quarterly Cash Dividend (GlobeNewswire)
Apr-21-26 05:00PM	embecta to Report Fiscal Second Quarter Financial Results (GlobeNewswire)
Mar-20-26 06:35AM	Embecta agrees to acquire Owen Mumford (Medical Device Network)
Mar-19-26 10:37AM	Embecta to buy Owen Mumford for up to $201M (MedTech Dive)
06:30AM	embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited (GlobeNewswire)
Feb-11-26 04:10PM	embecta names new Chairman of the Board and Lead Independent Director (GlobeNewswire)
Feb-05-26 05:30PM	Embecta Q1 Earnings Call Highlights (MarketBeat) -7.75%
02:02PM	Loading…
02:02PM	Embecta Corp (EMBC) Q1 2026 Earnings Call Highlights: Strategic Progress Amidst Market Challenges (GuruFocus.com)
06:30AM	Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results (GlobeNewswire)
06:00AM	embecta Announces Quarterly Cash Dividend (GlobeNewswire)
Jan-22-26 05:00PM	embecta to Report Fiscal First Quarter Financial Results (GlobeNewswire) -9.44%
Dec-18-25 05:00PM	embecta to Participate at the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire)
Nov-25-25 02:01PM	Embecta Corp (EMBC) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges (GuruFocus.com) -7.24%
06:30AM	Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2026 Financial Guidance (GlobeNewswire)
06:00AM	embecta Announces Quarterly Cash Dividend (GlobeNewswire)
Nov-20-25 07:50AM	EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth? (Zacks)
Nov-17-25 05:00PM	embecta announces changes to Board of Directors (GlobeNewswire)
Nov-14-25 06:30AM	embecta Announces Major New Commitment to Direct Relief on World Diabetes Day (GlobeNewswire)
Nov-11-25 05:00PM	embecta to Report Fiscal Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Oct-06-25 05:15AM	Best Value Stocks to Buy for October 6th (Zacks)
Sep-15-25 08:06AM	Best Income Stocks to Buy for September 15th (Zacks)
05:37AM	New Strong Buy Stocks for September 15th (Zacks)
Sep-09-25 04:12AM	Best Value Stocks to Buy for September 9th (Zacks)
Aug-26-25 05:00PM	embecta to Participate in Investor Events (GlobeNewswire)
Aug-25-25 09:30AM	Embecta Corp. (EMBC) Crossed Above the 200-Day Moving Average: What That Means for Investors (Zacks)
Aug-12-25 09:55AM	Wall Street Analysts Predict a 25.69% Upside in Embecta Corp. (EMBC): Here's What You Should Know (Zacks)
Aug-09-25 03:03AM	Embecta Corp (EMBC) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Progress ... (GuruFocus.com)
Aug-08-25 06:30AM	Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results (GlobeNewswire) +18.53%
06:00AM	embecta Announces Quarterly Cash Dividend (GlobeNewswire)
Jul-24-25 05:00PM	embecta to Report Fiscal Third Quarter 2025 Financial Results (GlobeNewswire)
Jul-13-25 12:27AM	BTIG Lowers PT on Embecta Corp. (EMBC) to $25, Keeps a Buy Rating (Insider Monkey)
Jul-10-25 11:13AM	Mizuho Lowers PT on Embecta Corp. (EMBC) to $13 From $15, Keeps a Neutral Rating (Insider Monkey)
May-27-25 05:00PM	embecta to Participate in Investor Events (GlobeNewswire) +5.09% -6.31%
May-22-25 06:30AM	embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day (GlobeNewswire) -14.97%
May-13-25 10:50AM	Embecta restructures again, outlines tariff costs (MedTech Dive)
May-10-25 05:16AM	Q2 2025 Embecta Corp Earnings Call (Thomson Reuters StreetEvents)
03:03AM	Embecta Corp (EMBC) Q2 2025 Earnings Call Highlights: Strategic Growth Amid Revenue Decline (GuruFocus.com)
May-09-25 12:10PM	Why Is Embecta Stock Falling On Friday? (Benzinga) -10.00%
07:40AM	Embecta Corp. (EMBC) Tops Q2 Earnings Estimates (Zacks)
06:30AM	Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results (GlobeNewswire)
06:00AM	embecta Announces Quarterly Cash Dividend (GlobeNewswire)
May-08-25 05:15PM	Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates (Zacks) +6.66%
May-07-25 11:35AM	2024 Total Dividend Income And Portfolio Update (Seeking Alpha)
Apr-28-25 07:30AM	Embecta to host Analyst and Investor Day on May 22, 2025 (GlobeNewswire)
Apr-22-25 03:51AM	Beyond the drug: Closing the knowledge gap for injectable diabetes meds (Pharma Voice)
Apr-21-25 05:00PM	embecta to Report Fiscal Second Quarter 2025 Financial Results (GlobeNewswire)
Apr-01-25 08:05AM	Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations (GlobeNewswire)
Feb-19-25 03:36PM	Embecta Corp. (EMBC): Among Last Weeks Worst Dividend Stocks (Insider Monkey)
Feb-18-25 05:00PM	embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference (GlobeNewswire)
Feb-07-25 02:09AM	Embecta Corp (EMBC) Q1 2025 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... (GuruFocus.com)
Feb-06-25 07:45AM	Embecta Corp. (EMBC) Tops Q1 Earnings and Revenue Estimates (Zacks)
06:30AM	Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results (GlobeNewswire)
06:00AM	embecta Announces Quarterly Cash Dividend (GlobeNewswire)
Jan-23-25 05:00PM	embecta to Report Fiscal First Quarter 2025 Financial Results (GlobeNewswire)
Dec-19-24 05:00PM	embecta to Participate at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 08:50AM	Here Is Why Bargain Hunters Would Love Fast-paced Mover Embecta Corp. (EMBC) (Zacks)
Dec-06-24 06:00AM	Embecta to cut 125 jobs after ending insulin patch pump (MedTech Dive)
Nov-27-24 06:40AM	Embecta to discontinue insulin patch pump program, initiates restructuring plan (TipRanks) +10.11%
02:02AM	Embecta Corp (EMBC) Q4 2024 Earnings Call Highlights: Strategic Shifts and Financial Performance (GuruFocus.com)
12:26AM	Q4 2024 Embecta Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-26-24 01:15PM	Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps (Benzinga) +29.77%
07:40AM	Embecta Corp. (EMBC) Tops Q4 Earnings and Revenue Estimates (Zacks)
06:40AM	Embecta discontinues insulin patch pump development (MedTech Dive)
06:30AM	Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs (GlobeNewswire)
06:00AM	embecta Announces Quarterly Cash Dividend (GlobeNewswire)
Nov-18-24 10:00AM	Inside a $400 billion bet on the brain-computer interface revolution (Yahoo Finance)
Nov-12-24 05:31PM	UPDATE - embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
05:00PM	embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Nov-07-24 06:30AM	embecta Celebrates National Diabetes Awareness Month by Ringing Nasdaq Closing Bell (GlobeNewswire) -6.37%
Sep-03-24 07:55AM	Embecta gets FDA nod for insulin patch pump (MedTech Dive)
06:30AM	embecta Announces FDA Clearance of its Disposable Patch Pump for Insulin Delivery Informed by the Unique Needs of People with Type 2 Diabetes (GlobeNewswire)
Aug-22-24 05:00PM	embecta to Participate in Investor Events (GlobeNewswire) +6.14%
Aug-12-24 09:35AM	Embecta Corp. (EMBC) Recently Broke Out Above the 20-Day Moving Average (Zacks)
09:30AM	Embecta Corp. (EMBC) Just Overtook the 200-Day Moving Average (Zacks)
Aug-10-24 08:18AM	Embecta Corp. (NASDAQ:EMBC) Q3 2024 Earnings Call Transcript (Insider Monkey)
Aug-09-24 10:52AM	EMBC Stock Earnings: Embecta Beats EPS, Beats Revenue for Q3 2024 (InvestorPlace) +7.32%
07:40AM	Embecta Corp. (EMBC) Tops Q3 Earnings and Revenue Estimates (Zacks)

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.

PresidentMr. Devdatt Kurdikar Ph.D.

Senior VP & CFOMr. Jacob P. Elguicze

Senior VPMr. Jeffrey Z. Mann

Senior VP & Chief Human Resources OfficerMs. Jean M. Casner

Senior Vice President of Global Manufacturing & Supply ChainMr. Shaun Curtis

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kurdikar Devdatt	President and CEO	Aug 12 '26	Buy	4.70	30,000	140,937	804,919	Aug 13 10:50 AM
Elguicze Jacob	SVP and CFO	Aug 12 '26	Buy	4.67	20,000	93,360	309,139	Aug 13 10:48 AM
Mann Jeffrey Z	Pres, Pharm Svc&Prod Mgmt, CLO	Aug 12 '26	Buy	4.99	20,000	99,800	262,915	Aug 13 10:47 AM
HOMBACH ROBERT J.	Director	Aug 12 '26	Buy	4.97	45,000	223,848	109,587	Aug 13 10:45 AM

SPTX Seaport Therapeutics Inc daily Stock Chart

Peers: AVLN ABCL ABSI ABEO AAPG ACAD ABVX ARWR ABOS ARQT

| Held by: VTI VXF SCHA SBIO SCHB VTWO WCEO VTWG VTWV VTHR

Index	-
Market Cap	1.29B
Enterprise Value	1.02B
Income	-
Sales	-
Book/sh	7.89
Cash/sh	5.11
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	54
IPO	May 01, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.05
P/C	4.72
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	18.00
Current Ratio	18.00
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-2.62
EPS next Q	-0.58
EPS this Y	85.72%
EPS next Y	41.89%
EPS next 5Y	55.96%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 03 BMO
EPS/Sales Surpr.	-186.91% -

Insider Own	67.29%
Insider Trans	3.19%
Inst Own	9.69%
Inst Trans	26.82%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	11.26%
SMA50	19.65%
SMA200	25.90%
Trades

Shs Outstand	53.53M
Shs Float	17.51M
Short Float	15.75%
Short Ratio	14.31
Short Interest	2.76M
52W High	24.65 -2.24%
52W Low	14.85 62.24%
Volatility	5.59% 6.79%
ATR (14)	1.45
RSI (14)	66.26
Beta	-
Rel Volume	0.41
Avg Volume	192.77K
Volume	42,127

Perf Week	4.34%
Perf Month	17.82%
Perf Quarter	46.02%
Perf Half Y	-
Perf YTD	14.73%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.33
Target Price	38.00
Prev Close	23.80
Price	24.09
Change %	1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-15-26	Initiated	H.C. Wainwright	Buy	$50
May-26-26	Initiated	Stifel	Buy	$30
May-26-26	Initiated	Leerink Partners	Outperform	$35
May-26-26	Initiated	JP Morgan	Overweight	$42
May-26-26	Initiated	Citigroup	Buy	$35

Aug-03-26 07:00AM	Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress (Business Wire)
Jun-09-26 02:00AM	PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers (Business Wire) +9.01%
Jun-08-26 07:00AM	Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers (Business Wire)
Jun-01-26 07:00AM	Seaport Therapeutics to Participate in Two Upcoming Investor Conferences (Business Wire) -5.83%

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company, which engages in the provision of inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company was founded on April 1, 2024 and is headquartered in Boston, MA.

Founder & Non-Employee Chair of the BoardDr. Steven M. Paul M.D.

FounderMs. Daphne Zohar

Co-Founder & Chief Scientific OfficerDr. Michael Cunyuan Chen Ph.D.

Chief Medical Officer & President of Clinical DevelopmentDr. Antony Loebel M.D.

Chief Financial OfficerMs. Lauren A. White M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HOMBACH ROBERT J.	Director	Jun 22 '26	Buy	18.14	13,000	235,768	13,000	Jun 24 06:05 AM
ARCH Venture Partners XII, LLC	10% Owner	May 04 '26	Buy	18.00	1,100,000	19,800,000	6,294,951	May 04 06:02 PM

EMBC

Embecta Corp

SPTX

Seaport Therapeutics Inc

Upgrade your Finviz experience